The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.

Backed by the Economic Development Board (EDB), the hub was launched on Nov 14 at the Lilly Digital Health and Lilly Centre ...

is a fully owned subsidiary of Eli Lilly & Company. LCCP was established (as Lilly-NUS Centre for Clinical Pharmacology Pte ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

The company expects to have Phase 2 data later this year ... GIPR is involved in insulin release and glycemic control. Rival drugs from Eli Lilly and Viking Therapeutics also target GIPR, but they ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Allogene Therapeutics has dropped plans to target one of its allogeneic CAR-Ts at leukemia in the face of competition from ...